Infiltrating lobular carcinoma—a comparison of diagnosis, management and outcome with infiltrating duct carcinoma

Molland, J. Gail; Donnellan, Michael; Janu, Norman C.; Carmalt, Hugh; Kennedy, Catherine; Gillett, David J.

doi:10.1016/j.breast.2004.03.004

Cited by 108 publications

(103 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reported re-excision rates in ILC after breast conserving surgery (BCS) range from 29 to 67% [1][2][3][4][5]. In 16-48% of patients with ILC local surgical therapy is still converted to mastectomy after failure of BCS [1,[5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast

Mann

Loo

Wobbes

et al. 2009

Breast Cancer Res Treat

183

107

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast

Mann

Loo

Wobbes

et al. 2009

Breast Cancer Res Treat

183

107

View full text Add to dashboard Cite

“…Although treatment for stage-matched ductal versus lobular carcinomas is similar [9], several studies have shown that ILC is a distinct entity of breast cancer that differs from IDC not only in histological and clinical features [10,11] but also in the risk factors [12], genomic profiles [13], global transcription programs [14], immunophenotype [15] and response to systemic therapy [11,16,17]. Such studies suggest that lobular tumour development and progression may follow a distinct pathway from ductal tumours.…”

Section: Introductionmentioning

confidence: 99%

“…In addition, it has been reported that ILC is less responsive to chemotherapy [3,21], lacks potential benefit of HER2 targeted therapy [16,17], being typically HER2 negative, but is more often HR positive and responsive to adjuvant hormonal therapy (HT) [11,22,23]. Reported prognosis of ILC varies and has been reported to be worse [1,9,[24][25][26][27], no different [17,[28][29][30][31][32], or better [6] than that with IDC.…”

Section: Introductionmentioning

confidence: 99%

The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology

Rakha

Gill

El-Sayed

et al. 2008

Breast Cancer Res Treat

View full text Add to dashboard Cite

“…However, clinical follow-up data and the patterns of metastasis suggest that their development and progression are diff erent 26,31 . The treatment for stage-matched tumors is similar 18 but lobular carcinomas are often resistant to neoadjuvant therapy 21 . Although patients with ILCs are older, have low grade tumors and less lymphatic vascular invasion, they have no survival advantage compared with IDCs 16 .…”

Section: Introductionmentioning

confidence: 99%

Novel Immunohistochemical Markers for the Differentiation of Lobular and Ductal Invasive Breast Carcinomas

Turashvili¹,

Bouchal²,

Ehrmann³

et al. 2007

BIOMED PAP

View full text Add to dashboard Cite

Aims. Invasive ductal and lobular carcinomas are the most common histological types of breast cancer. The loss of E-cadherin expression has been suggested to be the most reliable marker for invasive lobular carcinoma. The aim of our study was to identify the diagnostic usefulness of novel markers in the diff erentiation of these tumor types.Methods. We examined tissue microarrays (TMA) which were constructed from surgical specimens of 119 breast cancer patients. TMA consisted of 80 ductal carcinomas, 29 lobular carcinomas and special type cancers. TMA sections were stained using standard immunohistochemical methods. Monoclonal mouse antibodies against E-cadherin, cytokeratin 5/6 and 17, and polyclonal mouse antibodies against EMP1, DDR1, PRKCI and DVL1 were used.Results. E-cadherin was absent in 93.3 % of lobular tumors compared with only 15 % of ductal tumors (p < 0.0001). EMP1 and DVL1 were overexpressed in lobular tumors (93.1 % and 96.5 %, respectively), whereas PRKCI and DDR1 were positive in ductal cancers (90 % and 96.2 %, respectively). Reduced expression or absence of both cytokeratins 5/6 and 17 was found in both tumor tissues in comparison to normal terminal duct lobular units (p < 0.0001).Conclusions. Apart from the well-established marker, E-cadherin, proteins examined on TMA slides by immunohistochemistry (EMP1, DVL1, DDR1, PRKCI) may represent novel tissue markers helpful in the diff erentiation of ductal and lobular breast cancers. Further studies with larger sets of patients are desirable, to verify the complete immunohistochemical profi les of various histological types of breast cancer and determine the prognostic and predictive signifi cance of novel markers. BACKGROUND

show abstract

Infiltrating lobular carcinoma—a comparison of diagnosis, management and outcome with infiltrating duct carcinoma

Cited by 108 publications

References 28 publications

The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast

The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast

The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology

Novel Immunohistochemical Markers for the Differentiation of Lobular and Ductal Invasive Breast Carcinomas

Contact Info

Product

Resources

About